TITLE

Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor

AUTHOR(S)
Gyger, M; Stuart, R K; Perreault, C
PUB. DATE
July 2000
SOURCE
Bone Marrow Transplantation;7/1/2000, Vol. 26 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The use of mobilized peripheral blood (PB) stem cells for autologous transplantation initially generated much enthusiasm because of enhanced engraftment in comparison to marrow stem cells and avoidance of general anesthesia for the donor. Its application to the allogeneic setting seemed inevitable. For obvious ethical reasons, allogeneic donors are mobilized with cytokines only, mainly granulocyte colony-stimulating factor (G-CSF). Results from preliminary studies suggest that in comparison to standard bone marrow transplants, outcomes such as engraftment, host-versus-graft reaction, graft-versus-host disease, graft-versus-leukemia and immunological reconstitution may be different. Surprisingly, G-CSF, previously recognized as a late acting lineage-specific factor for neutrophil production, not only disrupts homeostasis between stem cells and their microenvironment, but also induces significant quantitative and qualitative changes in the accessory cell compartment, affecting lymphocytes, monocytes, natural killer, dendritic, and stromal cells. Furthermore, mobilization of huge numbers of non-professional antigen presenting cells (CD34+ stem cells) amplifies the tolerizing potential of PB stem cell grafts. Thus, G-CSF mobilization provides PB transplants with different immunobiologic properties in comparison to standard bone marrow grafts. Whether these immunobiologic differences will lead to better transplant outcomes remains to be shown through much awaited results of large randomized clinical trials. Bone Marrow Transplantation (2000) 26, 1–16.
ACCESSION #
8888242

 

Related Articles

  • Immune reconstitution following allogeneic peripheral blood stem cell transplants. Shenoy, S; Mohanakumar, T; Todd, G; Westhoff, W; Dunnigan, K; Adkins, D R; Brown, R A; DiPersio, J F // Bone Marrow Transplantation;2/15/99, Vol. 23 Issue 4, p335 

    Growth factor-mobilized peripheral blood stem cells (PBSCs) engraft rapidly in myeloablated recipients compared to conventional BM, but this procedure also mobilizes mature lymphocytes and monocytes which can impact immune reconstitution and GVHD. Hence, we serially evaluated immune...

  • Allogeneic myeloablative transplantation for patients aged 50 years and over. Yanada, M.; Emi, N.; Naoe, T.; Sakamaki, H.; Iseki, T.; Hirabayashi, N.; Karasuno, T.; Chiba, S.; Atsuta, Y.; Hamajima, N.; Takahashi, S.; Kato, S. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p29 

    Summary:Allogeneic hematopoietic stem cell transplantation (HSCT) has been performed mainly for young patients due to concern about the high incidence of treatment-related mortality (TRM). Recent advances to reduce TRM by using peripheral blood stem cells or nonmyeloablative conditioning...

  • A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors. Lee, K.-E.; Mun, Y. C.; Nam, S.-H.; Kwon, J. M.; Lee, S. M.; Lee, M.-A.; Yoo, E.-S.; Ahn, J.-Y.; Kim, J.-H.; Seong, C.-M. // Bone Marrow Transplantation;Dec2005, Vol. 36 Issue 12, p1027 

    Summary:The efficacy of mobilizing peripheral blood progenitor cells (PBPC) with continuous intravenous (c.i.v.) administration of rhG-CSF was randomly compared to subcutaneous (s.c.) administration, in 15 normal donors in each arm of the study for 6 days. The percentage and absolute numbers of...

  • Optimization of allogeneic transplant conditioning: not the time for dogma. Deeg, H. J.; Maris, M. B.; Scott, B. L.; Warren, E. H. // Leukemia (08876924);Oct2006, Vol. 20 Issue 10, p1701 

    Numerous reduced-intensity conditioning regimens for allogeneic hematopoietic cell transplantation are currently being explored, primarily in older patients and in individuals with comorbid conditions who are not eligible for conventional myeloablative conditioning regimens. There is agreement...

  • Signal One and Two Blockade Are Both Critical for Non-Myeloablative Murine HSCT across a Major Histocompatibility Complex Barrier. Langford-Smith, Kia J.; Sandiford, Zara; Langford-Smith, Alex; Wilkinson, Fiona L.; Jones, Simon A.; Wraith, J. Ed; Wynn, Robert F.; Bigger, Brian W. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Non-myeloablative allogeneic haematopoietic stem cell transplantation (HSCT) is rarely achievable clinically, except where donor cells have selective advantages. Murine non-myeloablative conditioning regimens have limited clinical success, partly through use of clinically unachievable cell doses...

  • dualism.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p697 

    Definitions of the term "dualism," which could pertain to the theory that various blood cells come from two types of stem cells, are presented.

  • Blood brothers. Richardson, Sarah // Discover;Jan2000, Vol. 21 Issue 1, p63 

    Reports on research where neural stem cells were transformed into blood cells in mice.

  • Hematopoietic stem cells: Are they CD34-positive or CD34-negative? Nakauchi, Hiromitsu // Nature Medicine;Sep1998, Vol. 4 Issue 9, p1009 

    New findings add to the growing evidence that some stem cells in the bone marrow do not express the CD34 marker, which is currently used to select stem cells for transplantation (pages 1038?1045).

  • Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Imashuku, S.; Hibi, S.; Todo, S.; Sako, M.; Inoue, M.; Kawa, K.; Koike, K.; Iwai, A.; Tsuchiya, S.; Akiyama, Y.; Kotani, T.; Kawamura, Y.; Hirosawa, M.; Hasegawa, D.; Kosaka, Y.; Yamaguchi, H.; Ishii, E.; Kato, K.; Ishii, M.; Kigasawa, H. // Bone Marrow Transplantation;3/15/99, Vol. 23 Issue 6, p569 

    Seventeen cases (age at onset, 1 month to 18 years; M/F, 9/8) of hemophagocytic syndrome which received allogeneic hematopoietic stem cell transplantation (SCT) in Japan during the period 1988–1998 are reported. The patients consisted of six familial inheritance-proven erythrophagocytic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics